Xilio Therapeutics Inc
XLO
NASDAQ
Biotechnology
$9.17
USD
+0.16 (+1.78%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $54.14M
Volume 8.1K
Revenue
$64.09M
TTM
+327.3%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-21.83M
TTM
+61.2%
YoY
Operating Cash Flow
$-60.60M
TTM
-354.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 8.1 | 19.1 | 13.7 | 12.6 | 18.7 |
YoY Growth | +243.0% | +742.5% | +693.9% | +331.7% | +131.2% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 8.1 | 19.1 | 13.7 | 12.6 | 18.7 |
Selling, General & Administrative | 7.1 | 6.7 | 7.4 | 6.9 | 7.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.5 | 21.0 | 25.5 | 26.8 | 22.2 |
Operating Income | -14.4 | -1.9 | -11.8 | -14.1 | -3.5 |
EBITDA | -14.0 | -1.6 | -11.5 | -13.8 | -3.2 |
Other Income / Expense | -1.5 | -14.4 | 22.2 | 4.6 | -2.9 |
Total Other Income / Expense | -1.5 | -14.4 | 22.2 | 4.6 | -2.9 |
Income Before Income Taxes | -15.8 | -16.3 | 10.4 | -9.5 | -6.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -15.8 | -16.3 | 10.4 | -9.5 | -6.4 |
Consolidated Net Income / Loss | -15.8 | -16.3 | 10.4 | -9.5 | -6.4 |
Net Income Attributable to Common Shareholders | -15.8 | -16.3 | 10.4 | -9.5 | -6.4 |
Basic EPS | -$2.30 | -$1.54 | $0.95 | -$0.58 | -$0.33 |
Diluted EPS | -$2.30 | -$1.54 | $0.95 | -$0.58 | -$0.33 |
Basic Shares Outstanding | 6.9M | 10.3M | 10.9M | 16.3M | 19.4M |
Diluted Shares Outstanding | 6.9M | 10.3M | 10.9M | 16.3M | 19.4M |